Summary of COVID-19 trimodulin studies

1. Agafina et al., Efficacy and safety of trimodulin in patients with severe COVID-19: results from a randomised, placebo-controlled, double-blind, multicentre, phase II trial (ESsCOVID)

166 patient trimodulin late treatment RCT: 17% higher mortality (p=0.7), 2% lower progression (p=1), and 9% longer ventilation (p=0.62).
RCT 166 severe COVID-19 patients on non-invasive ventilation or high-flow oxygen showing no significant difference in clinical deterioration or mortality with trimodulin treatment compared to placebo. In a post hoc analysis of a subgroup with early systemic inflammation, excluding patients with CRP > 150 mg/L and/or D-dimer ≥ 3 mg/L and/or platelets < 130 × 109/L at baseline, there was lower clinical deterioration or mortality, without statistical significance in the FAS. Authors hypothesize that trimodulin may reduce inflammation-driven progression if administered earlier before advanced disease develops.
Aug 2024, European J. Medical Research, https://eurjmedres.biomedcentral.com/articles/10.1186/s40001-024-02008-x, https://c19p.org/agafina